ITRM$0.5993
$0.6075
Chart
Performance
Key Stats
AI ITRM Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
HoldIterum Therapeutics plc exhibits potential in the anti-infective space but faces significant financial challenges and an uncertain path to consistent profitability. While recent EPS beats offer some encouragement, the overall financial health and ongoing losses warrant a cautious approach. Thematic exposure to antibiotic resistance is present but overshadowed by company-specific risks.
Thematic
Iterum Therapeutics operates in the critical area of combating drug-resistant bacterial infections. The growing global threat of antimicrobial resistance (AMR) provides a strong underlying thematic tailwind for companies developing novel antibiotics. However, the company's ability to capitalize on this theme is heavily dependent on its clinical and commercial execution.
Fundamental
Iterum Therapeutics faces substantial financial headwinds. The company has consistently reported significant losses and negative earnings per share. While recent EPS figures show smaller losses than historical periods, revenue is minimal, and the company is not yet profitable. The balance sheet shows increasing debt and negative total equity.
Technical
Iterum Therapeutics' stock price is trading significantly below its 52-week high and has experienced substantial declines over various periods, indicating bearish sentiment. While short-term technical indicators on a 1-minute and 5-minute basis suggest some buying pressure, longer-term indicators (1-day) are predominantly bearish, signaling potential for continued downward pressure.
| Factor | Score |
|---|---|
| Antimicrobial Resistance (AMR) | 85 |
| Pipeline & Product Approval | 70 |
| Competitive Landscape | 60 |
| Regulatory Environment | 75 |
| Healthcare Spending Trends | 55 |
| Factor | Score |
|---|---|
| Valuation | 10 |
| Profitability | 15 |
| Growth | 0 |
| Balance Sheet Health | 5 |
| Cash Flow | 20 |
| Earnings Per Share (EPS) | 40 |
| Factor | Score |
|---|---|
| Trend Analysis | 20 |
| Momentum | 40 |
| Volume Confirmation | 50 |
| Support & Resistance | 60 |
| Short-term Oscillators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (3)
Potentially Undervalued based on Price
The current price of $0.8025 is significantly below its 52-week high of $3.02. The price is also nearing its 52-week low of $0.801, suggesting potential undervaluation.
Oversold Indicators on Shorter Timeframes
Several shorter-term technical indicators (e.g., RSI on 15m, 30m, 1h, 2h, 4h, 1d, Stochastic %K on multiple timeframes, Commodity Channel Index on multiple timeframes, Williams Percent Range on multiple timeframes) suggest the stock may be oversold and potentially due for a bounce.
Bearish Points (10)
Negative EPS and Surprise Misses
EPS (TTM) is negative (-$0.94). Several recent quarterly EPS estimates have been missed (e.g., Q1 2025 actual vs. estimate, Q4 2024 estimate miss by 50%), indicating profitability challenges.
Negative and Unreliable P/E Ratio
The Price-to-Earnings (P/E) ratio is negative (-1.8 TTM, -2.9 for 2024), making it an unreliable valuation metric and indicating the company is not currently profitable on a trailing basis.
Calendar
August 2025
11
Next Earnings Date
H: $
A: $
L: $
Profile
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Seasonals
Price Target
7.00 USD
The 39 analysts offering 1 year price forecasts for ITRM have a max estimate of 9.00 and a min estimate of 5.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Developer of Alisertib (MLN8237), an Aurora Kinase A (AKA) inhibitor, which is the same mechanism of action as ITRM's lead candidate ITRI-066, making it a direct competitor in the AKA inhibitor space.
Weight: 95
Major global pharmaceutical company with an extensive and diverse oncology pipeline, including numerous targeted therapies and kinase inhibitors, positioning it as a broad competitor and potential acquirer in the cancer drug development landscape.
Weight: 94
Global pharmaceutical leader with a significant and active oncology division, frequently developing and commercializing targeted therapies and small molecule drugs that could compete with or complement ITRM's focus.
Weight: 93
Global pharmaceutical giant with a robust and expanding oncology portfolio, known for both internal development and strategic acquisitions of innovative oncology companies, making it a major competitor or potential acquirer.